|6 June 2016|
England/South Korea
Treating life-threatening diseases such as a cancer will be the target of a pioneering new partnership.
Oxford BioMedica and leading South Korean gene and cell therapy company Green Cross LabCell – a subsidiary of Green Cross Holdings – have entered into a Research & Development collaboration which will focus on identifying and developing gene modified natural killer (NK) cell-based therapeutics for treatment of life-threatening diseases such as cancer.
John Dawson, CEO of Oxford BioMedica, said: “We are very excited to form a key partnership with Green Cross LabCell, who have the industry-leading production platform for NK cell therapeutics for cancer. Over the years Green Cross LabCell has built a significant depth of scientific, technical and industrial expertise in NK cells that is difficult to find elsewhere.
“We are therefore delighted to be collaborating with Green Cross LabCell in a new partnership which brings our LentiVector® delivery platform and expertise to the relationship and which builds on our existing partnerships with other companies including Novartis, Sanofi, GSK and Immune Design. We believe that our collaboration will lead to the generation of a rich pipeline of novel gene-modified NK cell therapeutics for both companies.”
